Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
FRA:72X0's 14-Day RSI is ranked worse than 79.82% of 867
companies
in the Medical Devices & Instruments industry
Industry Median: 52.79
vs FRA:72X0: 55.31
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
MicroPort CardioFlow Medtech 14-Day RSI Related Terms
FRA:72X0 vs ABT, SYK, MDT: 14-Day RSI Comparison
For the Medical Devices subindustry, MicroPort CardioFlow Medtech's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MicroPort CardioFlow Medtech 14-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MicroPort CardioFlow Medtech's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where MicroPort CardioFlow Medtech's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MicroPort CardioFlow Medtech (FRA:72X0) has a 14-Day RSI of 55.31 as of Aug. 14, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on MicroPort CardioFlow Medtech and its competitors. According to the industry distribution chart, MicroPort CardioFlow Medtech ranks #692 out of 867 companies in the Medical Devices & Instruments industry, placing it in the top 79.8%.
Is MicroPort CardioFlow Medtech's 14-Day RSI too high?
MicroPort CardioFlow Medtech's current 14-Day RSI is 55.31. The Medical Devices & Instruments industry median 14-Day RSI is 52.79. MicroPort CardioFlow Medtech's value of 55.31 is 4.8% above this industry median. Based on the distribution chart, MicroPort CardioFlow Medtech ranks #692 out of 867 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, MicroPort CardioFlow Medtech has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MicroPort CardioFlow Medtech's 14-Day RSI compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, MicroPort CardioFlow Medtech ranks #692 out of 867 companies for 14-Day RSI. This places MicroPort CardioFlow Medtech in the lower half of its industry. The industry median 14-Day RSI is 52.79. MicroPort CardioFlow Medtech's value of 55.31 is 4.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Medical Devices & Instruments company?
The median 14-Day RSI among Medical Devices & Instruments companies is 52.79, based on 867 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MicroPort CardioFlow Medtech's current 14-Day RSI of 55.31 is 4.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on MicroPort CardioFlow Medtech and its competitors. For the Medical Devices & Instruments industry, the median 14-Day RSI is 52.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MicroPort CardioFlow Medtech's current 14-Day RSI is 55.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MicroPort CardioFlow Medtech stock overvalued right now?
Based on GuruFocus' analysis, MicroPort CardioFlow Medtech (FRA:72X0) is currently considered Possible Value Trap. The stock's GF Value™ is €0.62, compared to a current price of €0.13 — trading 78.5% below its estimated fair value. The current 14-Day RSI is 55.31 and 4.8% above the Medical Devices & Instruments industry median of 52.79. MicroPort CardioFlow Medtech's overall GF Score™ is 41/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For MicroPort CardioFlow Medtech (FRA:72X0), the current 14-Day RSI is 55.31 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MicroPort CardioFlow Medtech (FRA:72X0) Overvalued in 2026?
Based on GuruFocus' analysis, MicroPort CardioFlow Medtech stock appears to be undervalued.
The current stock price of €0.13 is trading 78.5% below its estimated GF Value™ of €0.62.
GuruFocus considers MicroPort CardioFlow Medtech to be Possible Value Trap.
Key valuation signals for FRA:72X0:
14-Day RSI: 55.31
GF Value™: €0.62 vs. price of €0.13 (78.5% below fair value)
Industry Position: 4.8% above the Medical Devices & Instruments median (#692 of 867)
No single metric tells the full story. See the FRA:72X0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MicroPort CardioFlow Medtech Corp is a medical device company in China focusing on the research, development, and commercialization of transcatheter and surgical solutions for valvular heart diseases. The company's product portfolio consists of VitaFlow, VitaFlow Liberty, Angelguide and AnchorMan. The Group derives revenue from the sales of medical devices through appointed distributors. It derives maximum revenue from PRC.
41GF Score
Get the complete analysis for FRA:72X0
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:72X0 has been successfully added to your 
